The primary goal of tyrosine kinase inhibitor (TKI) therapy for patients with chronic myeloid
leukemia is survival, which is achieved by the vast majority of patients. The initial response …

Background: The advent of tyrosine kinase inhibitors (TKI) has decisively improved the
survival of patients with chronic myeloid leukemia (CML). Many patients achieve deep …

Purpose The advent of tyrosine kinase inhibitor (TKI) therapies has revolutionized the
treatment of chronic myeloid leukemia (CML). The European LeukemiaNet (ELN) …

Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients
requires integration of clinical and laboratory monitoring. Assessment of molecular response …

With the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid
leukemia (CML) are steadily shifting. Long-term disease control on TKI therapy has been the …

Over the past two decades, tyrosine kinase inhibitors have become the foundation of chronic
myeloid leukemia (CML) treatment. The choice between imatinib and newer tyrosine kinase …

Imatinib was the first BCR‐ABL1 tyrosine kinase inhibitor (TKI) developed for the treatment
of patients with chronic myeloid leukemia (CML); subsequently, the introduction of more …

Tyrosine kinase inhibitor (TKI) therapy yields sustained cytogenetic remissions in most
patients with chronic‐phase chronic myeloid leukemia (CML). Peripheral blood quantitative …

Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic
and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic …

Abstract Purpose of Review Although tyrosine kinase inhibitors (TKIs) spectacularly improve
the disease burden and the overall survival of chronic myeloid leukemia patients, early …